Inotiv, Inc. will release Q1 2025 financial results on February 5, 2025, and host a conference call at 4:30 PM ET.
Quiver AI Summary
Inotiv, Inc. announced that it will release its financial results for the first quarter of fiscal 2025, which ended on December 31, 2024, on February 5, 2025, after market close. The company will hold a conference call to discuss these results at 4:30 p.m. Eastern Time on the same day. Interested parties can join the call via a dedicated phone number or by accessing a live webcast on the company's website. Inotiv specializes in contract research services aimed at supporting drug discovery and development, focusing on enhancing efficiency and reducing costs in bringing new drugs and medical devices to market. The release also notes potential risks and uncertainties that could impact the company's operations and financial condition.
Potential Positives
- Inotiv, Inc. is set to announce its financial results for the fiscal 2025 first quarter, indicating transparency and accountability in its financial reporting.
- The conference call scheduled for February 5, 2025, allows for direct engagement with investors and stakeholders, promoting open communication about the Company's performance.
- The Company emphasizes its commitment to supporting drug discovery and development, highlighting its role in improving efficiency and reducing costs in the pharmaceutical industry.
- The availability of a live webcast and replay of the financial results ensures accessibility for a wider audience, fostering investor interest and engagement.
Potential Negatives
- The upcoming financial results release may indicate ongoing challenges, particularly in light of unspecified impacts related to non-human primate matters, which could affect overall business operations.
- The mention of risks associated with compliance with the DOJ's Resolution and Plea Agreements suggests potential legal and financial vulnerabilities for the company.
- The presence of multiple uncertainties, including market demand fluctuations and compliance risks, may raise concerns among investors regarding the company's stability and future performance.
FAQ
When will Inotiv announce its fiscal 2025 first quarter results?
Inotiv will announce its fiscal 2025 first quarter results on February 5, 2025, after the market closes.
How can I participate in the Inotiv conference call?
To participate in the conference call, dial 1-800-579-2543 domestically or 1-785-424-1789 internationally.
What time is the Inotiv conference call scheduled?
The Inotiv conference call is scheduled for 4:30 p.m. Eastern Time on February 5, 2025.
Where can I access the webcast of Inotiv's conference call?
The live conference call webcast will be accessible in the Investors section of Inotiv's website.
Will there be a replay of the conference call available?
Yes, an online replay of the conference call will be available in the Investors section of Inotiv's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NOTV Insider Trading Activity
$NOTV insiders have traded $NOTV stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NOTV stock by insiders over the last 6 months:
- DAVID LANDMAN has made 2 purchases buying 123,529 shares for an estimated $513,998 and 0 sales.
- JOHN GREGORY BEATTIE (Chief Operating Officer) purchased 30,000 shares for an estimated $142,500
- MICHAEL J HARRINGTON purchased 10,000 shares for an estimated $39,822
- NIGEL BROWN purchased 7,500 shares for an estimated $31,950
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NOTV Hedge Fund Activity
We have seen 14 institutional investors add shares of $NOTV stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERICAN CENTURY COMPANIES INC removed 295,589 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $502,501
- KING LUTHER CAPITAL MANAGEMENT CORP removed 198,600 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $337,620
- THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. added 109,397 shares (+612.5%) to their portfolio in Q4 2024, for an estimated $452,903
- TWO SIGMA INVESTMENTS, LP removed 109,054 shares (-71.9%) from their portfolio in Q3 2024, for an estimated $185,391
- BANK OF AMERICA CORP /DE/ added 83,501 shares (+967.6%) to their portfolio in Q3 2024, for an estimated $141,951
- LAZARD ASSET MANAGEMENT LLC removed 77,200 shares (-74.2%) from their portfolio in Q3 2024, for an estimated $131,240
- SILVERBACK ASSET MANAGEMENT LLC removed 70,700 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $120,190
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Interested parties may participate in the call by dialing:
- 1-800-579-2543 (Domestic)
- 1-785-424-1789 (International)
-
INOTIV (Conference ID)
The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1703666&tp_key=aaee0f56f1
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://ir.inotiv.com/events-and-presentations/default.aspx .
About Inotiv
Inotiv, Inc.
is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here:
https://www.inotiv.com/
.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the impact of recent events related to non-human primate matters on the Company’s business, operations, results, financial condition, cash flows, and assets, the Company’s ability to comply with covenants under its credit agreement, compliance with the Resolution and Plea Agreements with the DOJ and the expected impacts on the Company related to the compliance plan, compliance monitor, and the expected financial commitments, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
Company Contact | Investor Relations |
Inotiv, Inc. | LifeSci Advisors |
Beth A. Taylor, Chief Financial Officer | Steve Halper |
(765) 497-8381 | (646) 876-6455 |
[email protected] | [email protected] |